secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0000950170-25-088738
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage reports OpRegen 36-month data: +9 ETDRS letters in extensive-coverage GA patients
--------------------------------------------------------------------------------

- Mean BCVA gain of +6.2 letters (n=10) persisting through 36 months vs. +5.5 at 24 months.
- Patients with extensive bleb coverage (n=5) showed mean +9.0 letters at 36 months vs. +7.4 at 24 months.
- Retinal structure improvements (RPEDC, ELM) on OCT sustained in treated eyes; untreated fellow eyes declined.
- Phase 2a GAlette study enrolling (NCT05626114) testing proprietary surgical delivery devices.
- CEO states data challenges view that GA causes irreversible damage; effects durable after single injection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017025088738/0000950170-25-088738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017025088738/lctx-20250623.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-088738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer